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BACKGROUND
The efficacy of interleukin-6 receptor antagonists in critically ill patients with 
coronavirus disease 2019 (Covid-19) is unclear.
METHODS
We evaluated tocilizumab and sarilumab in an ongoing international, multifactorial, 
adaptive platform trial. Adult patients with Covid-19, within 24 hours after starting 
organ support in the intensive care unit (ICU), were randomly assigned to receive 
tocilizumab (8 mg per kilogram of body weight), sarilumab (400 mg), or standard 
care (control). The primary outcome was respiratory and cardiovascular organ sup-
port–free days, on an ordinal scale combining in-hospital death (assigned a value 
of −1) and days free of organ support to day 21. The trial uses a Bayesian statistical 
model with predefined criteria for superiority, efficacy, equivalence, or futility. An 
odds ratio greater than 1 represented improved survival, more organ support–free 
days, or both.
RESULTS
Both tocilizumab and sarilumab met the predefined criteria for efficacy. At that 
time, 353 patients had been assigned to tocilizumab, 48 to sarilumab, and 402 to 
control. The median number of organ support–free days was 10 (interquartile range, 
−1 to 16) in the tocilizumab group, 11 (interquartile range, 0 to 16) in the sari-
lumab group, and 0 (interquartile range, −1 to 15) in the control group. The me-
dian adjusted cumulative odds ratios were 1.64 (95% credible interval, 1.25 to 2.14) 
for tocilizumab and 1.76 (95% credible interval, 1.17 to 2.91) for sarilumab as 
compared with control, yielding posterior probabilities of superiority to control of 
more than 99.9% and of 99.5%, respectively. An analysis of 90-day survival showed 
improved survival in the pooled interleukin-6 receptor antagonist groups, yielding 
a hazard ratio for the comparison with the control group of 1.61 (95% credible 
interval, 1.25 to 2.08) and a posterior probability of superiority of more than 
99.9%. All secondary analyses supported efficacy of these interleukin-6 receptor 
antagonists.
CONCLUSIONS
In critically ill patients with Covid-19 receiving organ support in ICUs, treatment 
with the interleukin-6 receptor antagonists tocilizumab and sarilumab improved 
outcomes, including survival. (REMAP-CAP ClinicalTrials.gov number, NCT02735707.)
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Globally, more than 112 million cas-es of coronavirus disease 2019 (Covid-19) have been reported, with more than 2.49 
million deaths.1 Only glucocorticoids are known 
to improve survival among severely ill patients.2 
The benefit from glucocorticoids in critically ill 
patients supports the concept that an excessive 
host inflammatory response is responsible for 
much of the serious illness and death from 
Covid-19.
Interleukin-6 is released in response to infec-
tion and stimulates inflammatory pathways as 
part of the acute-phase response. Tocilizumab and 
sarilumab are monoclonal antibodies that inhibit 
both membrane-bound and soluble interleukin-6 
receptors and are used to treat inflammatory 
conditions, such as rheumatoid arthritis, as well 
as cytokine release syndrome after chimeric anti-
gen receptor (CAR) T-cell therapy (tocilizumab). 
Their clinical use has been described in Covid-193-5; 
however, randomized, controlled trials to date 
have largely been negative, with the most posi-
tive study showing a decreased risk of mechani-
cal ventilation but no effect on mortality.6-11 We 
investigated the effectiveness of tocilizumab and 
sarilumab on survival and organ support in criti-
cally ill patients with Covid-19 in the Random-
ized, Embedded, Multifactorial Adaptive Plat-
form Trial for Community-Acquired Pneumonia 
(REMAP-CAP).
Me thods
Trial Design and Oversight
REMAP-CAP is an international, adaptive platform 
trial designed to determine effective treatment 
strategies for patients with severe pneumonia in 
both pandemic and nonpandemic settings. The 
design of REMAP-CAP and its first results, re-
garding glucocorticoids in patients with Covid-19, 
were published previously.12,13
Patients eligible for the platform are assessed 
for eligibility to potentially undergo randomiza-
tion to multiple interventions across multiple do-
mains. A “domain” covers a common therapeutic 
area (e.g., antiviral therapy) and contains two or 
more interventions (including control; e.g., “no 
antiviral”). Patients are randomly assigned to one 
intervention in each domain for which they are 
eligible. REMAP-CAP is defined by a master 
(“core”) protocol with individual appendixes for 
each domain, regional governance, and adapta-
tions for a declared pandemic (see the protocol, 
available with the full text of this article at 
NEJM.org).
The trial was designed and managed by an 
international trial steering committee whose mem-
bers were unaware of the trial group assignments 
and an independent data and safety monitoring 
board whose members were aware of the trial 
group assignments. The trial is approved by rel-
evant regional ethics committees and is con-
ducted in accordance with Good Clinical Practice 
guidelines and the principles of the Declaration 
of Helsinki. Written or verbal informed consent, 
in accordance with regional legislation, is obtained 
from all the patients or their surrogates.
The trial has multiple international funders. 
Roche Products and Sanofi supported the trial 
through provision of tocilizumab and sarilumab 
in the United Kingdom. The funders as well as 
Roche and Sanofi had no role in designing the 
trial, analyzing the data, writing the manuscript, 
or making the decision to submit the manuscript 
for publication. All the authors vouch for the 
completeness and accuracy of the data and for 
the fidelity of the trial to the protocol and sta-
tistical analysis plan.
Patients
Critically ill patients, 18 years of age or older, 
with either clinically suspected or microbiologi-
cally confirmed Covid-19 who were admitted to 
an intensive care unit (ICU) and receiving respi-
ratory or cardiovascular organ support were 
classified as having a severe disease state and 
were eligible for enrollment in the Covid-19 Im-
mune Modulation Therapy domain. Respiratory 
organ support was defined as invasive or nonin-
vasive mechanical ventilation, including through 
high-flow nasal cannulae if the flow rate was 
more than 30 liters per minute and the fraction 
of inspired oxygen was more than 0.4. Cardio-
vascular organ support was defined as the intra-
venous infusion of any vasopressor or inotrope. 
Patients were excluded if there was a presump-
tion that death was imminent with a lack of 
commitment to full support or if they had previ-
ously participated in REMAP-CAP within 90 days. 
Patients had to be enrolled within 24 hours after 
starting organ support in the ICU. Additional 
exclusion criteria, specific to the Immune Modu-
lation Therapy domain, are listed in the Supple-
mentary Appendix, available at NEJM.org.
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Randomization
The Immune Modulation Therapy domain in-
cluded five interventions — two interleukin-6 
receptor antagonists, tocilizumab and sarilumab; 
an interleukin-1 receptor antagonist, anakinra; 
interferon beta-1a; and control (no immune 
modulation). Investigators at each site prespeci-
fied at least two interventions, one of which had 
to be control, to which patients would be ran-
domly assigned. Participants were assigned by 
means of a centralized computer program to each 
intervention, starting with balanced assignment 
for tocilizumab, sarilumab, or control, with ac-
tual proportions dependent on the number of 
interventions available at each site.
Tocilizumab, at a dose of 8 mg per kilogram of 
actual body weight (up to a maximum of 800 mg), 
was administered as an intravenous infusion over 
a period of 1 hour; this dose could be repeated 
12 to 24 hours later at the discretion of the treat-
ing clinician if clinical improvement was judged 
insufficient. Sarilumab, at a dose of 400 mg, was 
administered as an intravenous infusion once only. 
All investigational drugs were dispensed by local 
pharmacies and were open label.
Procedures
Other aspects of patient care were provided ac-
cording to the standard of care at each site. In 
addition to receiving assignments in this domain, 
participants could be randomly assigned to other 
interventions within other domains, depending 
on domains active at the site, patient eligibility, 
and consent (see the protocol and www.remapcap 
.org). Randomization to the Corticosteroid domain 
for Covid-19 closed on June 17, 2020.13 Thereafter, 
glucocorticoids were allowed according to the 
recommended standard of care. Although clini-
cal staff were aware of the intervention assign-
ment of individual patients, neither they nor the 
members of the international trial steering com-
mittee were provided any information about ag-
gregate patient outcomes.
Outcome Measures
The primary outcome was the number of respi-
ratory and cardiovascular organ support–free days 
up to day 21. The definitions of respiratory and 
cardiovascular organ support were the same as 
in the inclusion criteria. In this composite ordinal 
outcome, all deaths within the hospital are as-
signed the worst outcome (–1). Among survivors, 
days free of respiratory and cardiovascular organ 
support are calculated up to day 21, such that a 
higher number represents faster recovery. In a pre-
vious Food and Drug Administration–approved 
trial, 1.5 days was considered to be a minimal 
clinically important difference.14 Secondary out-
comes were all prespecified, and details are pro-
vided in the Supplementary Appendix.
Statistical Analysis
REMAP-CAP uses a Bayesian design with no 
maximum sample size. Regular, interim analyses 
are performed and randomization continues, po-
tentially with response-adaptive randomization 
with preferential assignment to the interventions 
that appear most favorable, until predefined sta-
tistical criteria are met.
The primary analysis was generated from a 
Bayesian cumulative logistic model, which cal-
culated posterior probability distributions of or-
gan support–free days to day 21 (primary outcome) 
on the basis of evidence accumulated in the trial 
and the prior probability distribution (the assumed 
previous knowledge). Prior distributions for in-
dividual treatment effects were neutral.
The primary model was adjusted for location 
(site, nested within country), age (categorized into 
six groups), sex, and time period (2-week calendar 
epochs) to account for rapid changes in clinical 
care and outcomes over time during the pan-
demic. The model contained treatment effects for 
each intervention within each domain and pre-
specified treatment-by-treatment interactions 
across domains. The treatment effects for tocili-
zumab and sarilumab were “nested” in the 
model with a hierarchical prior distribution 
sharing the same neutral prior distribution in an 
overall “interleukin-6 receptor antagonist ef-
fect,” but distinct intervention-specific effects 
were estimated. When consistent effects are ob-
served for tocilizumab and sarilumab, the poste-
rior distribution for each intervention effect is 
shrunk toward the overall estimate of the inter-
leukin-6 receptor antagonist effect.15
The primary analysis was conducted by the 
statistical analysis committee in all the patients 
with severe disease randomly assigned to any do-
main up to November 19, 2020 (and with complete 
follow-up). The inclusion of additional patients 
who were enrolled outside the Immune Modula-
tion Therapy domain allows incorporation of all 
information, which provides robust estimation 
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of the coefficients of all covariates, according to 
the principle of the REMAP-CAP design.12,13 Not 
all patients were eligible for all domains or for 
all interventions (dependent on active domains 
and interventions at the site, eligibility criteria, 
and patient or surrogate consent). Therefore, the 
model included covariate terms reflecting each 
patient’s domain eligibility, such that the esti-
mate of the effectiveness of an intervention, rela-
tive to any other intervention within that domain, 
was generated from patients who might have 
been eligible to be randomly assigned to those 
interventions within the domain.
The cumulative log odds for the primary out-
come were modeled such that a value greater 
than 0 reflects an increase in the cumulative log 
odds for the outcome of organ support–free days, 
implying benefit. Missing outcomes were not 
imputed. The model was fit with the use of a 
Markov chain Monte Carlo algorithm that drew 
iteratively (10,000 draws) from the joint posterior 
distribution, which allowed calculation of poste-
rior odds ratios with their 95% credible intervals 
and the probability that each intervention (includ-
ing control) was optimal (i.e., better than all other 
treatments tested) in the domain, that an interven-
tion was superior to control (efficacy), that two 
noncontrol interventions were equivalent, or that 
an intervention was futile as compared with 
control. An odds ratio greater than 1 represents 
improved survival, more organ support–free days, 
or both. The predefined statistical criteria for 
determining trial conclusions and for triggering 
the disclosure of results were as follows: a pos-
terior probability of greater than 99% that an 
intervention was more effective than all other 
interventions; an inferiority conclusion if the 
posterior probability that an intervention was 
more effective than all other interventions was 
less than 0.25%; intervention efficacy if the pos-
terior probability that the odds ratio was greater 
than 1.0 as compared with control was greater 
than 99%; intervention futility if the posterior 
probability that the odds ratio was greater than 
1.2 as compared with control was less than 5%; 
and equivalence if the probability that the odds 
ratio was between 0.83 and 1.2 for two noncon-
trol interventions was greater than 90%.
Analysis of the primary outcome was then 
repeated in a second model that used only data 
from patients enrolled in domains that had stopped 
and were unblinded at the time of analysis with 
no adjustment for assignment in other ongoing 
domains. The secondary outcomes were also 
analyzed in this second model. One subgroup 
analysis, based on terciles of serum C-reactive 
protein levels at enrollment, was prespecified. 
Further details of all analyses are provided in the 
Supplementary Appendix. Prespecified analyses 
are listed in Section 15 of the statistical analysis 
plan, available with the protocol. Data manage-
ment and summaries were created with the use 
of R software, version 3.6.0; the primary analysis 
was computed with R software, version 4.0.0, with 
the use of the rstan package, version 2.21.1. Ad-
ditional data management and analyses were 
performed with SQL Server 2016; SPSS software, 
version 26; and Stata software, version 14.2.
R esult s
Enrollment and Randomization
The first patient with Covid-19 was enrolled in 
REMAP-CAP on March 9, 2020, and the first pa-
tient underwent randomization in the Immune 
Modulation Therapy domain on April 19 as to-
cilizumab became available. Sarilumab only be-
came available on June 20. On the basis of an 
interim analysis as of October 28, the indepen-
dent data and safety monitoring board reported 
that tocilizumab had met the statistical criteria 
for efficacy (posterior probability, 99.75%; odds 
ratio, 1.87; 95% credible interval, 1.20 to 2.76). 
According to the protocol, further assignment to 
control closed on November 19, with random-
ization continuing between different active im-
mune modulation interventions. At that time, 
2046 patients who had severe disease had under-
gone randomization in at least one REMAP-CAP 
domain and 895 had undergone randomization 
in the Immune Modulation Therapy domain (366 
were assigned to tocilizumab, 48 to sarilumab, 
412 to control, and 69 to other interventions 
within the domain) at 113 sites across six countries 
(Fig. 1). Thirty patients subsequently withdrew 
consent, and 11 patients had missing primary out-
comes. After a subsequent interim analysis, the 
data and safety monitoring board reported that 
sarilumab had also met the statistical criteria for 
efficacy, so these results are also reported.
Patients
Baseline characteristics were balanced across in-
tervention groups and typical of a critically ill 
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Figure 1. Screening, Enrollment, Randomization, and Inclusion in Analysis.
Patients who were ineligible for the platform or the Immune Modulation Therapy domain could meet more than one ineligibility criteri‑
on; full details are provided in the Supplementary Appendix. Contraindications to agents in the Immune Modulation Therapy domain in‑
clude hypersensitivity, elevated levels of alanine aminotransferase or aspartate aminotransferase, thrombocytopenia, and pregnancy. 
Among patients who underwent randomization to an Immune Modulation Therapy domain intervention, the group assigned to receive 
no immune modulation only included patients when tocilizumab or sarilumab was a randomization option (i.e., direct concurrent con‑
trols). Other interventions included anakinra, interferon beta‑1a, and no immune modulation when tocilizumab or sarilumab was not 
available as a randomization option (i.e., nondirect controls). The primary analysis of alternative interventions within the Immune Mod‑
ulation Therapy domain is estimated from a model that adjusts for patient factors and for assignment to interventions in other do‑
mains. To obtain the most reliable estimation of the effect of these patient factors and of other interventions on the primary outcome, 
all the patients who were enrolled in the severe coronavirus disease 2019 (Covid‑19) cohort (for whom there is consent and follow‑up) 
are included. However, the model also factors eligibility for the Immune Modulation Therapy domain and its interventions, such that 
the final estimate of the effectiveness of an Immune Modulation Therapy domain intervention relative to any other within that domain is 
generated from the patients who might have been eligible to undergo randomization to those interventions within the domain. ICU de‑
notes intensive care unit, and REMAP‑CAP Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community‑Acquired 
Pneumonia.
2046 Had severe disease and were enrolled
in at least one REMAP-CAP domain
3301 Patients admitted to ICU with suspected or proven Covid-19 were
assessed for eligibility between March 9 and November 19, 2020
895 Underwent randomization to an Immune Modulation
Therapy domain intervention
1151 Were ineligible or not assessed for Immune Modulation Therapy domain
665 Were at site that was not active for Immune Modulation Therapy domain
486 Were at site that was active for Immune Modulation Therapy domain
1 Did not have Covid-19 samples taken
245 Were admitted to ICU more than 24 hr earlier
6 Were receiving long-term immune modulation treatment
17 Had received immune modulation during hospital admission
68 Had known immune suppression
23 Were enrolled in another trial
110 Had contraindication to agents in domain
67 Had treating physician who considered randomization not to be in
patient’s best interest
28 Declined prospective consent
4 Had assignment that was never revealed 
764 Were ineligible for platform
283 Were at site that was not active for Immune Modulation Therapy domain
and were not enrolled in another domain
208 Were at site that was active for Immune Modulation Therapy domain but
were not enrolled in any domain
366 Were assigned to receive
tocilizumab
13 Withdrew consent
3 Had outcome that was
not available
10 Withdrew consent
5 Had outcome that was
not available
353 Were included at baseline
350 Were included in final
analysis
3 Had outcome that was
not available
48 Were included at baseline
45 Were included in final
analysis
48 Were assigned to receive
sarilumab
402 Were included at baseline
397 Were included in final
analysis
412 Were assigned to receive
no immune modulation
7 Withdrew consent
1 Had outcome that was
not available
62 Were included at baseline
61 Were included in final
analysis
69 Were assigned to receive
another intervention
25 Withdrew consent
51 Had outcome that was
not available
1075 Were used for covariate
adjustment
1151 Were assigned to receive
intervention in another domain
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Age — yr 61.5±12.5 63.4±13.4 61.1±12.8 61.4±12.7
Male sex — no. (%) 261 (74) 39 (81) 283 (70) 629 (73)
Race or ethnic group — no./total no. (%)§
White 160/228 (70) 29/39 (74) 206/279 (74) 420/580 (72)
Asian 41/228 (18) 8/39 (21) 47/279 (17) 99/580 (17)
Black 12/228 (5) 1/39 (3) 9/279 (3) 23/580 (4)
Mixed 2/228 (1) 0/39 5/279 (2) 7/580 (1)
Other 13/228 (6) 1/39 (3) 12/279 (4) 31/580 (5)
Body‑mass index¶
Patients evaluated 342 39 377 815
Median (IQR) 30.5 (26.9–34.9) 29.2 (26.0–33.8) 30.9 (27.1–34.9) 30.5 (26.8–34.9)
APACHE II score‖
Patients evaluated 337 42 381 820
Median (IQR) 13 (8–19) 10 (7–16) 12 (8–18) 12 (8–19)
Confirmed SARS‑CoV‑2 infection — no./total 
no. (%)**
284/345 (82) 44/47 (94) 334/394 (85) 715/847 (84)
Median time to enrollment (IQR)
From hospital admission — days 1.2 (0.8–2.8) 1.4 (0.9–2.8) 1.2 (0.8–2.8) 1.2 (0.8–2.8)
From ICU admission — hr 13.1 (6.6–19.0) 16.0 (11.4–20.8) 14.0 (6.8–19.5) 13.6 (6.6–19.4)
Acute respiratory support — no./total no. (%)
None or supplemental oxygen only 1/353 (<1) 0/48 2/402 (<1) 3/865 (<1)
High‑flow nasal cannulae 101/353 (29) 17/48 (35) 110/402 (27) 249/865 (29)
Noninvasive ventilation only 147/353 (42) 23/48 (48) 169/402 (42) 359/865 (42)
Invasive mechanical ventilation 104/353 (29) 8/48 (17) 121/402 (30) 254/865 (29)
Vasopressor support — no./total no. (%) 63/353 (18) 4/48 (8) 79/402 (20) 163/865 (19)
Pao2:Fio2
Patients evaluated 335 35 354 780
Median (IQR) 115 (89–162) 126 (99–157) 118 (89–169) 116.5 (89–165)
Laboratory values††
C‑reactive protein
Patients evaluated 207 37 244 533
Median (IQR) — μg/ml 150 (85–221) 136 (105–204) 130 (71–208) 136 (79–208)
d‑dimer
Patients evaluated 159 20 172 385
Median (IQR) — ng/ml 832 (461–1763) 828 (355–1435) 1010 (500–2115) 910 (480–1916)
*  Plus–minus values are means ±SD. Percentages may not total 100 because of rounding. Fio2 denotes the fraction of inspired oxygen, ICU 
intensive care unit, IQR interquartile range, and Pao2 the partial pressure of arterial oxygen.
†  Control patients include all the patients randomly assigned to standard care who were also eligible to be randomly assigned to tocilizum‑
ab or sarilumab (i.e., direct concurrent controls).
‡  All patient includes those who underwent randomization in the Immune Modulation Therapy domain, with assignment to control (including where 
tocilizumab and sarilumab were not randomization options; i.e., nondirect controls), tocilizumab, sarilumab, anakinra, or interferon beta‑1a.
§  Race and ethnic group were reported by the patients. Data collection was not approved in Canada and continental Europe. “Other” in‑
cludes “declined” and “multiple.”
¶  The body‑mass index is the weight in kilograms divided by the square of the height in meters.
‖  Scores on the Acute Physiology and Chronic Health Evaluation (APACHE) II range from 0 to 71, with higher scores indicating greater se‑
verity of illness.
**  Infection with severe acute respiratory syndrome coronavirus 2 (SARS‑CoV‑2) was confirmed by a respiratory tract polymerase‑chain‑reac‑
tion test.
††  Values were from the sample collected closest to randomization, up to 8 hours before randomization. If no samples were collected up to 
8 hours before the time of randomization, the sample collected closest to the time of randomization up to 2 hours after randomization 
was used (other than for Pao2:Fio2, which was a prerandomization value only). Laboratory values were only added to the case‑report form 
on August 6, 2020.
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population with Covid-19 (Table 1 and Table S1 
in the Supplementary Appendix). All but 3 patients 
were receiving respiratory support at the time of 
randomization, including oxygen through high-
flow nasal cannulae (29%), noninvasive ventila-
tion (42%), and invasive mechanical ventilation 
(29%). The majority of patients (707) were en-
rolled after June 17 and the announcement of the 
dexamethasone result from the RECOVERY tri-
al16,17; of these patients, 93% (610 of 654) were 
treated with glucocorticoids at enrollment or 
within the following 48 hours (Table S2). Of the 
158 patients recruited before June 17, a total of 
107 underwent randomization in the Corticoste-
roid domain within REMAP-CAP, with 41 as-
signed to a 7-day course of hydrocortisone, 39 to 
shock-dependent hydrocortisone, and 27 to no 
hydrocortisone.13 Remdesivir use was recorded 
in 265 of 807 patients (33%).
In the tocilizumab group, 92% of the patients 
received at least one dose, and 29% received a 
second dose at the discretion of the treating clini-
cian. In the sarilumab group, 90% of the patients 
received the assigned drug. In the control group, 
2% of the patients were given one of the immune-
modulating drugs outside the trial protocol.
Primary Outcome
The median number of organ support–free days 
was 10 (interquartile range, −1 to 16) in the to-
cilizumab group, 11 (interquartile range, 0 to 16) 
in the sarilumab group, and 0 (interquartile range, 
−1 to 15) in the control group (Table 2 and Fig. 2). 
The median adjusted odds ratios (primary mod-
el) were 1.64 (95% credible interval, 1.25 to 2.14) 
for tocilizumab and 1.76 (95% credible interval, 
1.17 to 2.91) for sarilumab as compared with 
control, yielding posterior probabilities of supe-
riority of more than 99.9% and of 99.5%, respec-
tively. The in-hospital mortality in the pooled 
interleukin-6 receptor antagonist groups was 27% 
(108 of 395 patients), as compared with 36% 
(142 of 397 patients) in the control group. The 
median adjusted odds ratios for in-hospital sur-
vival were 1.64 (95% credible interval, 1.14 to 2.35) 
for tocilizumab and 2.01 (95% credible interval, 
1.18 to 4.71) for sarilumab as compared with 
control, yielding posterior probabilities of supe-
riority of 99.6% and 99.5%, respectively. The re-
sults of the sensitivity analyses were consistent 
with those of the primary analysis (Table 2, Ta-
bles S3 and S4, and the analysis reports by the 
statistical analysis committee and the interna-
tional trial steering committee in the Supplemen-
tary Appendix). The estimates of the treatment 
effect in patients treated with either tocilizumab 
or sarilumab and glucocorticoids in combina-
tion were greater than the estimates for any in-
tervention on its own, and the estimated interac-
tion between interleukin-6 receptor antagonists 
and glucocorticoids was additive and slightly in 
the direction of synergistic, but with substantial 
variability in the estimate (Tables S5 and S6).
Secondary Outcomes
The secondary outcomes are listed in Figure 3 
and Table S7. Tocilizumab and sarilumab were 
effective across all secondary outcomes, includ-
ing 90-day survival, time to ICU and hospital 
discharge, and improvement in the World Health 
Organization ordinal scale at day 14.18 Similar 
effects were seen across subgroups (Tables S8 
and S9).
Nine serious adverse events were reported in 
the tocilizumab group, including one secondary 
bacterial infection, five bleeding events, two car-
diac events, and one deterioration in vision. Eleven 
serious adverse events were reported in the con-
trol group, including four bleeding events and 
seven thromboses. No serious adverse events were 
reported in the sarilumab group.
Discussion
We found that in critically ill patients with 
Covid-19, the interleukin-6 receptor antagonists 
tocilizumab and sarilumab were both effective 
as compared with the current standard of care, 
which included glucocorticoids in the majority of 
patients (>80%). The benefit was consistent across 
primary and secondary outcomes and across sub-
groups and secondary analyses.
Multiple observational and ex vivo laboratory 
studies have shown that interleukin-6 is an im-
portant cytokine associated with disease severity 
and mortality.19-21 A recent genomic analysis in 
critically ill patients with Covid-19 showed that 
genetic variants in the interleukin-6 inflamma-
tory pathway are associated with life-threatening 
disease.22 These observations support a therapeu-
tic strategy of inhibiting interleukin-6 pathways 
in patients with severe Covid-19.
Our trial should be compared with other trials 
of interleukin-6 receptor antagonists in Covid-19. 
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Many previously reported trials included less se-
verely ill patients and excluded patients already 
receiving respiratory support.6-8 In those trials, 
no clear evidence suggested that tocilizumab was 
effective at preventing disease progression, and 
no benefit with respect to survival was seen. One 
trial was stopped early at an interim analysis 
owing to safety concerns, although it should be 
noted that mortality in the control group was 
remarkably low (2 of 64 patients, 3%) and the 
time to hospital discharge was shorter in the 
tocilizumab group.11 The EMPACTA (Evaluating 
Minority Patients with Actemra) trial showed 
that patients who received tocilizumab were less 










Median (IQR) 10 (−1 to 16) 11 (0 to 16) 0 (−1 to 15)
Adjusted odds ratio
Mean 1.65±0.23 1.83±0.44 1
Median (95% credible interval) 1.64 (1.25 to 2.14) 1.76 (1.17 to 2.91) 1
Probability of superiority to control — % >99.9 99.5 —
Subcomponents of organ support–free days
In‑hospital death — no./total no. (%) 98/350 (28) 10/45 (22) 142/397 (36)
Concurrent with tocilizumab randomization — — 127/355 (36)†
Concurrent with sarilumab randomization — — 19/63 (30)†
Median no. of days free of organ support in survi‑
vors (IQR)
14 (7 to 17) 15 (6 to 17) 13 (4 to 17)
Primary in-hospital survival
Adjusted odds ratio
Mean 1.66±0.31 2.25±0.96 1
Median (95% credible interval) 1.64 (1.14 to 2.35) 2.01 (1.18 to 4.71) 1
Probability of superiority to control — % 99.6 99.5 —
Secondary analysis of primary outcome
Adjusted odds ratio
Mean 1.68±0.24 1.84±0.44 1
Median (95% credible interval) 1.66 (1.26 to 2.18) 1.77 (1.18 to 2.90) 1
Probability of superiority to control — % >99.9 99.6 —
Secondary analysis of primary in-hospital survival
Adjusted odds ratio
Mean 1.67±0.31 2.24±0.94 1
Median (95% credible interval) 1.65 (1.15 to 2.34) 2.00 (1.17 to 4.69) 1
Probability of superiority to control — % 99.6 99.4 —
*  Plus–minus values are means ±SD. The primary analysis of organ support–free days and in‑hospital death used data 
from all the patients enrolled in the trial who met coronavirus disease 2019 (Covid‑19) severe state criteria and who 
underwent randomization within at least one domain (1928 patients), with adjustment for age, sex, time period, site, 
region, domain, intervention eligibility, and intervention assignment. Secondary analyses were restricted to patients en‑
rolled in the Immune Modulation Therapy domain and any domains that have ceased recruitment (Corticosteroid and 
Covid‑19 Antiviral domains) (1293 patients), with adjustment for age, sex, time period, site, region, domain, interven‑
tion eligibility, and intervention assignment. Definitions of outcomes are provided in the trial protocol. All models are 
structured such that a higher odds ratio is favorable.
†  The numbers of patients do not sum to the numbers in the entire control group because at some sites, both tocilizum‑
ab and sarilumab were concurrently available as potential randomization assignments alongside control.
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likely than those who received placebo to un-
dergo mechanical ventilation or to die by day 28 
(hazard ratio, 0.56; 95% confidence interval [CI], 
0.33 to 0.97), although no substantial difference 
in overall mortality was noted (weighted differ-
ence, 2.0 percentage points; 95% CI, −5.2 to 
7.8).9 The COVACTA trial, in which approxi-
mately 38% of the patients were mechanically 
ventilated, showed no significant difference be-
tween the tocilizumab and placebo groups with 
respect to clinical status or mortality at day 28, 
although the time to hospital discharge was 
shorter with tocilizumab (hazard ratio, 1.35; 
95% CI, 1.02 to 1.79).10 The data for a trial of 
sarilumab are not yet available, but press re-
leases indicated no benefit in the whole popula-
Figure 2. Distributions of Organ Support–free Days.
Panel A shows the cumulative proportion of patients for each intervention group according to day, with death shown first. Curves that 
rise more gradually indicate a more favorable distribution in the number of days alive and free of organ support. The height of each 
curve at “−1” indicates the in‑hospital mortality for each intervention. The height of each curve at any time point indicates the propor‑
tion of patients who had that number of organ support–free days or fewer (e.g., the height at day 10 indicates the proportion of patients 
with ≤10 organ support–free days). The difference in the height of the curves at any point represents the difference in the percentile in 
the distribution of organ support–free days associated with that number of days alive and free of organ support. Panel B shows organ 
support–free days as horizontally stacked proportions according to intervention group. Red represents worse outcomes, and blue repre‑
sents better outcomes. The median adjusted odds ratios from the primary analysis, which used a Bayesian cumulative logistic model, 
were 1.64 (95% credible interval, 1.25 to 2.14) and 1.76 (95% credible interval, 1.17 to 2.91) for the tocilizumab and sarilumab groups, 
respectively, as compared with control, yielding probabilities of superiority to control of more than 99.9% and of 99.5%, respectively. 
Panels C and D are similar to Panels A and B but with the tocilizumab and sarilumab groups pooled together. The median adjusted odds 
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tion but a trend toward reduced mortality in the 
critically ill group and a trend toward harm in a 
subgroup not mechanically ventilated.23,24
We saw both a shorter time to clinical im-
provement and lower mortality with tocilizumab 
and with sarilumab than with control. It is there-
fore possible that the maximum clinical benefit 
from interleukin-6 inhibition (i.e., improved sur-
vival) is seen in the most severely ill patients 
with Covid-19, who are at the highest risk for 
death. However, it is important to note that in 
our trial, patients had to be enrolled within 24 
hours after starting organ support in the ICU. 
This may be an important factor to maximize 
effectiveness: treating critically ill patients early, 
while any developing organ dysfunction may be 
more reversible.
Investigators have proposed using C-reactive 
protein or other inflammatory markers to select 
patients with a hyperinflammatory state for treat-
ment.6,8 We saw beneficial effects of interleukin-6 
inhibition across all C-reactive protein subgroups 
Figure 3. Time-to-Event Analyses.
Shown are Kaplan–Meier curves for survival according to individual intervention group (Panel A) and survival with the tocilizumab and 
sarilumab groups pooled together (Panel B). There were 109 deaths in the pooled intervention group (99 with tocilizumab and 10 with 
sarilumab) and 142 in the control group. This resulted in a hazard ratio of 1.61 (95% CI, 1.25 to 2.08), yielding a more than 99.9% poste‑
rior probability of superiority of the interleukin‑6 receptor antagonists to control. Also shown are the time to ICU discharge according to 
individual intervention group (Panel C) and the time to hospital discharge according to individual intervention group (Panel D). All haz‑










































































































































Hazard ratio with tocilizumab,
1.59 (95% credible interval, 1.24–2.05)
Hazard ratio with sarilumab,
1.82 (95% credible interval, 1.22–3.38)
Hazard ratio with pooled interleukin-6 receptor antagonists,
1.61 (95% credible interval, 1.25–2.08)  
Hazard ratio with tocilizumab,
1.42 (95% credible interval, 1.18–1.70)
Hazard ratio with sarilumab,
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1.41 (95% credible interval, 1.18–1.70)
Hazard ratio with sarilumab,
1.51 (95% credible interval, 1.17–2.40)
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in this critically ill population. Although Covid-19 
has been described as producing a “cytokine 
storm,”25 recent studies have shown that sys-
temic levels of cytokines may not be as high as 
seen with other causes of sepsis and acute respi-
ratory distress syndrome.26 It may be that local 
inflammation, as evidenced by respiratory dys-
function, is a more useful indicator of which pa-
tients will benefit from interleukin-6 inhibition. 
Concern has been expressed about administering 
immune-modulating drugs, such as tocilizumab 
and sarilumab, to patients with critical illness 
due to infection with a novel virus. One consis-
tent result across all trials to date, including our 
trial, is that no increased incidences of serious 
adverse events were reported.
The pragmatic, international design of 
REMAP-CAP means that our results are probably 
generalizable to the wider critically ill patient 
population with Covid-19, although the standard 
of care may vary in other ICUs and over time, 
and other populations may include different 
high-risk patients. The trial has other limita-
tions. It uses an open-label design, but aware-
ness of intervention assignment is unlikely to 
affect the mortality component of the primary 
outcome. Because this is an early, preliminary 
report, some data are missing, including 11 out-
comes. Some patients remain in the hospital, so 
long-term outcomes may differ from the short-
term outcomes presented here. Because the trial 
has a Bayesian design, the results depend on a 
complex statistical model that may be unfamil-
iar to many clinicians. The multifactorial design 
also allows multiple interventions to be evaluated 
simultaneously, providing more efficient results 
and accounting for potential treatment-by-treat-
ment interactions. However, many of these inter-
ventions continue, and their effects and possible 
interactions are still to be reported.
In critically ill adult patients with Covid-19 
receiving organ support in ICUs, treatment with 
the interleukin-6 receptor antagonists tocilizumab 
and sarilumab improved outcomes, including 
survival.
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